A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide
Barbara Gamberi(University of Modena and Reggio Emilia), Igor Wolfgang Blau(Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie), Antonia Di Micco(National and Kapodistrian University of Athens), Barbara Rosettani(National and Kapodistrian University of Athens), Sarah Peters(Max Planck Society), Kari Remes(Turku University Hospital), Meletios Α. Dimopoulos(Korea University), Gerard Crotty, Monique C. Minnema(University Medical Center Utrecht), Björn Andréasson(NU Hospital Group), Miguel‐Teodoro Hernández(Hospital Universitario de Canarias), Eleni Tholouli(Manchester Royal Infirmary), Gianpietro Semenzato(University of Padua), Roman Hájek(University Hospital Ostrava), Elisabeth Kueenburg(National and Kapodistrian University of Athens), Christian Berthou(Centre Hospitalier Régional Universitaire de Brest), Joana Parreira(University of Lisbon), Pamela Bacon(National and Kapodistrian University of Athens), Jo Caers(University of Liège)
Cited by 2
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k